English Silicon Intelligence releases its financial report for 2025: cash reserves amount to 393 million US dollars, with new signed business cooperation agreements totaling over 1.3 billion US dollars.

Hong Kong-listed generative AI pharmaceutical leader Yingxi Intelligent released its first annual performance announcement after going public. During the reporting period, the company achieved revenues of $56.24 million, and was listed on the main board of the Hong Kong Stock Exchange on December 30, 2025, with a bank balance and cash balance of $393 million by the end of the year. With its self-developed integrated generative AI platform Pharma.AI, the company nominated 6 preclinical candidate drugs during the period, with a total of 8 projects making clinical progress, including 5 proprietary pipelines and 3 collaborative projects. The core pipeline Rentosertib showed good safety and tolerability in phase IIa studies of idiopathic pulmonary fibrosis, and dose-dependent improvement in declining lung function trend, with complete results published in "Nature Medicine." In terms of business expansion, the company added more than 10 collaborations during the period, with a total new contract value of approximately $1.3 billion; several projects also reached milestones and achieved returns.